



References

1. Nohr SB, Laurberg P, Borlum KG, Pedersen Km, Johannesen PL, Damm P. Iodine deficiency in pregnancy in Denmark. Regional variations and frequency of individual iodine supplementation. *Acta Obstet Gynecol Scand* 1993;72:350-3.
2. Glinoe D. Pregnancy and iodine. *Thyroid* 2001;11:471-81.
3. Hollowell JG, Staehling NW, Hannon WH, Flanders DW, Gunter EW, Maberly GF et al. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). *J Clin Endocrinol Metab* 1998;83:3398-400.
4. Wartofsky L, Glinoe D, Solomon d, Nagataki S, Lagasse R, Nagayama Y et al. Differences and similarities in the diagnosis and treatment of Graves disease in Europe, Japan and the United States. *Thyroid* 1990;1:129-35.
5. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. *JAMA* 1995;273:808-12.
6. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG et al. Treatment Guidelines for Patients with Thyroid Nodules and Well-differentiated Thyroid Cancer. *Arch Intern Med* 1996;156:2165-72.
7. Vanderpump MPJ, Ahlquist JAO, Franklyn JA and Clayton RN. Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. *Br Med J* 1996;313:539-44.
8. Laurberg P, Nygaard B, Glinoe D, Grussendorf M and Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. *Eur J Endocrinol* 1998;139:584-6.
9. Cobin RH, Gharib H, Bergman DA, Clark OH, Cooper DS, Daniels GH et al. AACE/AAES Medical/Surgical Guidelines for Clinical Practice: Management of Thyroid Carcinoma. *Endocrine Pract* 2001;7:203-20.
10. Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG et al. American Thyroid Association Guidelines for detection of thyroid dysfunction. *Arch Intern Med* 2000;160:1573-5.
11. Brandi ML, Gagel RJ, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C et al. Consensus Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. *J Clin Endocrinol Metab* 2001;86:5658-71.
12. Werner and Ingbar's "The Thyroid". A Fundamental and Clinical Text. Lippincott-Raven, Philadelphia 2000. Braverman LE and Utiger RD eds.
13. DeGroot LJ, Larsen PR, Hennemann G, eds. *The Thyroid and Its Diseases*. (www.thyroidmanager.org) 2000.
14. Piketty ML, D'Herbomez M, Le Guillouzie D, Lebtahi R, Cosson E, Dumont A et al. Clinical comparison of three labeled-antibody immunoassays of free triiodothyronine. *Clin Chem* 1996;42:933-41.
15. Sapin R, Schlienger JL, Goichot B, Gasser F and Grucker D. Evaluation of the Elecsys free triiodothyronine assay; relevance of age-related reference ranges. *Clin Biochem* 1998;31:399-404.
16. Robbins J. Thyroid hormone transport proteins and the physiology of hormone binding. In "Hormones in Blood". Academic Press, London 1996. Gray CH, James VHT, eds. pp 96-110.
17. Demers LM. Thyroid function testing and automation. *J Clin Ligand Assay* 1999;22:38-41.
18. Hollowell JG, Staehling NW, Hannon WH, Flanders WD, Gunter EW, Spencer CA et al. Serum thyrotropin, thyroxine and thyroid antibodies in the United States population (1988 to 1994): NHANES III. *J Clin Endocrinol Metab* 2002;87:489-99.
19. Wardle CA, Fraser WD and Squire CR. Pitfalls in the use of thyrotropin concentration as a first-line thyroid-function test. *Lancet* 2001;357:1013-4.
20. Spencer CA, LoPresti JS, Patel A, Guttler RB, Eigen A, Shen D et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. *J Clin Endocrinol Metab* 1990;70:453-60.
21. Meikle, A. W., J. D. Stringham, M. G. Woodward and J. C. Nelson. Hereditary and environmental influences on the variation of thyroid hormones in normal male twins. *J Clin Endocrinol Metab* 1988;66:588-92.

22. Andersen S, Pedersen KM, Bruun NH and Laurberg P. Narrow individual variations in serum T4 and T3 in normal subjects: a clue to the understanding of subclinical thyroid disease. *J Clin Endocrinol Metab* 2002;87:1068-72.
23. Cooper, D. S., R. Halpern, L. C. Wood, A. A. Levin and E. V. Ridgway. L-thyroxine therapy in subclinical hypothyroidism. *Ann Intern Med* 1984;101:18-24.
24. Biondi B, Fazio E, Palmieri EA, Carella C, Panza N, Cittadini A et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. *J Clin Endocrinol Metab* 1999;2064-7.
25. Hak AE, Pols HAP, Visser TJ, Drexhage HA, Hofman A and Witteman JCM. Subclinical Hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. *Ann Intern Med* 2000;132:270-8.
26. Michalopoulou G, Alevizaki M, Piperinos G, Mitsibounas D, Mantzos E, Adamopoulos P et al. High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism? *Eur J Endocrinol* 1998;138:141-5.
27. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC and Weintraub BD. Thyrotropin-secreting pituitary tumors. *Endocrine Rev* 1996;17:610-38.
28. Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL and Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity and treatment outcome in 25 patients followed at the National Institutes of Health. *J Clin Endocrinol Metab* 76 1999;:1089-94.
29. Oliveira JH, Persani L, Beck-Peccoz P and Abucham J. Investigating the paradox of hypothyroidism and increased serum thyrotropin (TSH) levels in Sheehan's syndrome: characterization of TSH carbohydrate content and bioactivity. *J Clin Endocrinol Metab* 2001;86:1694-9.
30. Uy H, Reasner CA and Samuels MH. Pattern of recovery of the hypothalamic-pituitary thyroid axis following radioactive iodine therapy in patients with Graves' disease. *Amer J Med* 1995;99:173-9.
31. Hershman JM, Pekary AE, Berg L, Solomon DH and Sawin CT. Serum thyrotropin and thyroid hormone levels in elderly and middle-aged euthyroid persons. *J Am Geriatr Soc* 1993;41:823-8.
32. Fraser CG. Age-related changes in laboratory test results. Clinical applications. *Drugs Aging* 1993;3:246-57.
33. Fraser CG. 2001. Biological Variation: from principles to practice. AACC Press, Washington DC.
34. Drinka PJ, Siebers M and Voeks SK. Poor positive predictive value of low sensitive thyrotropin assay levels for hyperthyroidism in nursing home residents. *South Med J* 1993;86:1004-7.
35. Vanderpump MPJ, Tunbridge WMG, French JM, Appleton D, Bates D, Rodgers H et al. The incidence of thyroid disorders in the community; a twenty year follow up of the Whickham survey. *Clin Endocrinol* 1995;43:55-68.
36. Sawin CT, Geller A, Kaplan MM, Bacharach P, Wilson PW, Hershman JM et al. Low serum thyrotropin (thyroid stimulating hormone) in older persons without hyperthyroidism. *Arch Intern Med* 1991;151:165-8.
37. Parle JV, Maisonneuve P, Sheppard MC, Boyle P and Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year study. *Lancet* 2001;358:861-5.
38. Nelson JC, Clark SJ, Borut DL, Tomei RT and Carlton EI. Age-related changes in serum free thyroxine during childhood and adolescence. *J Pediatr* 1993;123:899-905.
39. Adams LM, Emery JR, Clark SJ, Carlton EI and Nelson JC. Reference ranges for newer thyroid function tests in premature infants. *J Pediatr* 1995;126:122-7.
40. Lu FL, Yau KI, Tsai KS, Tang JR, Tsao PN and Tsai WY. Longitudinal study of serum free thyroxine and thyrotropin levels by chemiluminescent immunoassay during infancy. *T'aiwan Erh K'o i Hseh Hui Tsa Chih* 1999;40:255-7.
41. Zurakowski D, Di Canzio J and Majzoub JA. Pediatric reference intervals for serum thyroxine, triiodothyronine, thyrotropin and free thyroxine. *Clin Chem* 1999;45:1087-91.
42. Fisher DA, Nelson JC, Carlton EI and Wilcox RB. Maturation of human hypothalamic-pituitary-thyroid function and control. *Thyroid* 2000;10:229-34.
43. Fisher DA, Schoen EJ, La Franchi S, Mandel SH, Nelson JC, Carlton EI and Goshi JH. The hypothalamic-pituitary-thyroid negative feedback control axis in children with treated congenital hypothyroidism. *J Clin Endocrinol Metab* 2000;85:2722-7.

44. Penny R, Spencer CA, Frasier SD and Nicoloff JT. Thyroid stimulating hormone (TSH) and thyroglobulin (Tg) levels decrease with chronological age in children and adolescents. *J Clin Endocrinol Metab* 1983;56:177-80.
45. Verheecke P. Free triiodothyronine concentration in serum of 1050 euthyroid children is inversely related to their age. *Clin Chem* 1997;43:963-7.
46. Glinoe D, De Nayer P, Bourdoux P, Lemone M, Robyn C, van Steirteghem A et al. Regulation of maternal thyroid function during pregnancy. *J Clin Endocrinol Metab* 1990;71:276-87.
47. Glinoe D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. *Endocrinol Rev* 1997;18:404-33.
48. Weeke J, Dybkjaer L, Granlie K, Eskjaer Jensen S, Kjaerulff E, Laurberg P et al. A longitudinal study of serum TSH and total and free iodothyronines during normal pregnancy. *Acta Endocrinol* 1982;101:531-7.
49. Pedersen KM, Laurberg P, Iversen E, Knudsen PR, Gregersen HE, Rasmussen OS et al. Amelioration of some pregnancy associated variation in thyroid function by iodine supplementation. *J Clin Endocrinol Metab* 1993;77:1078-83.
50. Nohr SB, Jorgensen A, Pedersen KM and Laurberg P. Postpartum thyroid dysfunction in pregnant thyroid peroxidase antibody-positive women living in an area with mild to moderate iodine deficiency: Is iodine supplementation safe? *J Clin Endocrinol Metab* 2000;85:3191-8.
51. Panesar NS, Li CY and Rogers MS. Reference intervals for thyroid hormones in pregnant Chinese women. *Ann Clin Biochem* 2001;38:329-32.
52. Nissim M, Giorda G, Ballabio M, D'Alborton A, Bochicchio D, Orefice R et al. Maternal thyroid function in early and late pregnancy. *Horm Res* 1991;36:196-202.
53. Talbot JA, Lambert A, Anobile CJ, McLoughlin JD, Price A, Weetman AP et al. The nature of human chorionic gonadotropin glycoforms in gestational thyrotoxicosis. *Clin Endocrinol* 2001;55:33-9.
54. Jordan V, Grebe SK, Cooke RR, Ford HC, Larsen PD, Stone PR et al. Acidic isoforms of chorionic gonadotrophin in European and Samoan women are associated with hyperemesis gravidarum and may be thyrotrophic. *Clin Endocrinol* 1999;50:619-27.
55. Goodwin TM, Montoro M, Mestman JH, Pekary AE and Hershman JM. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. *J Clin Endocrinol Metab* 1992;75:1333-7.
56. Hershman JM. Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. *Thyroid* 1999;9:653-7.
57. McElduff A. Measurement of free thyroxine (T4) in pregnancy. *Aust NZ J Obst Gynecol* 1999;39:158-61.
58. Christofides N, Wilkinson E, Stoddart M, Ray DC and Beckett GJ. Assessment of serum thyroxine binding capacity-dependent biases in free thyroxine assays. *Clin Chem* 1999;45:520-5.
59. Roti E, Gardini E, Minelli R, Bianconi L, Flisi M. Thyroid function evaluation by different commercially available free thyroid hormone measurement kits in term pregnant women and their newborns. *J Endocrinol Invest* 1991;14:1-9.
60. Stockigt JR. Free thyroid hormone measurement: a critical appraisal. *Endocrinol Metab Clin N Am* 2001;30:265-89.
61. Mandel SJ, Larsen PR, Seely EW and Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. *NEJM* 1990;323:91-6.
62. Burrow GN, Fisher DA and Larsen PR. Maternal and fetal thyroid function. *N Engl J Med* 1994;331:1072-8.
63. Pop VJ, De Vries E, Van Baar AL, Waelkens JJ, De Rooy HA, Horsten M et al. Maternal thyroid peroxidase antibodies during pregnancy: a marker of impaired child development? *J Clin Endocrinol Metab* 1995;80:3561-6.
64. Haddow JE, Palomaki GE, Allan WC, K. G. Williams JR, Gagnon J, O'Heir CE et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *NEJM* 1999;341:549-55.
65. Pop VJ, Kuijpers JL, van Baar AL, Verkerk G, van Son MM, de Vijlder JJ et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. *Clin Endocrinol* 1999;50:147-8.

66. Radetti G, Gentili L, Paganini C, Oberhofer R, Deluggi I and Delucca A. Psychomotor and audiological assessment of infants born to mothers with subclinical thyroid dysfunction in early pregnancy. *Minerva Pediatr* 2000;52:691-8.
67. Surks MI and Sievert R. Drugs and thyroid function. *NEJM* 1995;333:1688-94.
68. Kailajarvi M, Takala T, Gronroos P, Tryding N, Viikari J, Irjala K et al. Reminders of drug effects on laboratory test results. *Clin Chem* 2000;46:1395-1400.
69. Brabant A, Brabant G, Schuermeyer T, Ranft U, Schmidt FW, Hesch RD et al. The role of glucocorticoids in the regulation of thyrotropin. *Acta Endocrinol* 1989;121:95-100.
70. Samuels MH and McDaniel PA. Thyrotropin levels during hydrocortisone infusions that mimic fasting-induced cortisol elevations: a clinical research center study. *J Clin Endocrinol Metab* 1997;82:3700-4.
71. Kaptein EM, Spencer CA, Kamiel MB and Nicoloff JT. Prolonged dopamine administration and thyroid hormone economy in normal and critically ill subjects. *J Clin Endocrinol Metab* 1980;51:387-93.
72. Geffner DL and Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidism. *Am J Med* 1992;93:61-8.
73. Meurisse M, Gollogly MM, Degauque C, Fumal I, Defechereux T and Hamoir E. Iatrogenic thyrotoxicosis: causal circumstances, pathophysiology and principles of treatment- review of the literature. *World J Surg* 2000;24:1377-85.
74. Martino E, Aghini-Lombardi F, Mariotti S, Bartelena L, Braverman LE and Pinchera A. Amiodarone: a common source of iodine-induced thyrotoxicosis. *Horm Res* 1987;26:158-71.
75. Martino E, Bartelena L, Bogazzi F and Braverman LE. The effects of amiodarone on the Thyroid. *Endoc Rev* 2001;22:240-54.
76. Daniels GH. Amiodarone-induced thyrotoxicosis. *J Clin Endocrinol Metab* 2001;86:3-8.
77. Harjai KJ and Licata AA. Effects of amiodarone on thyroid function. *Ann Intern Med* 1997;126:63-73.
78. Caron P. Effect of amiodarone on thyroid function. *Press Med* 1995;24:1747-51.
79. Bartelena L, Grasso L, Brogioni S, Aghini-Lombardi F, Braverman LE and Martino E. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. *J Clin Endocrinol Metab* 1994;78:423-7.
80. Eaton SE, Euinton HA, Newman CM, Weetman AP and Bennet WM. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. *Clin Endocrinol* 2002;56:33-8.
81. Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. *Thyroid* 1998;8:909-13.
82. Kusalic M and Engelsmann F. Effect of lithium maintenance therapy on thyroid and parathyroid function. *J Psych Neurosci* 1999;24:227-33.
83. Oakley PW, Dawson AH and Whyte IM. Lithium: thyroid effects and altered renal handling. *Clin Toxicol* 2000;38:333-7.
84. Mendel CM, Frost PH, Kunitake ST and Cavalieri RR. Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. *J Clin Endocrinol Metab* 1987;65:1259-64.
85. Iitaka M, Kawasaki S, Sakurai S, Hara Y, Kuriyama R, Yamanaka K et al. Serum substances that interfere with thyroid hormone assays in patients with chronic renal failure. *Clin Endocrinol* 1998;48:739-46.
86. Bowie LJ, Kirkpatrick PB and Dohnal JC. Thyroid function testing with the TDx: Interference from endogenous fluorophore. *Clin Chem* 1987;33:1467.
87. DeGroot LJ and Mayor G. Admission screening by thyroid function tests in an acute general care teaching hospital. *Amer J Med* 1992;93:558-64.
88. Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. *Endocrinol Rev* 1996;17:45-63.
89. Van den Berghe G, De Zegher F and Bouillon R. Acute and prolonged critical illness as different neuroendocrine paradigms. *J Clin Endocrinol Metab* 1998;83:1827-34.
90. Van den Berhe G. Novel insights into the neuroendocrinology of critical illness. *Eur J Endocrinol* 2000;143:1-13.
91. Wartofsky L and Burman KD. Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". *Endocrinol Rev* 1982;3:164-217.

92. Spencer CA, Eigen A, Duda M, Shen D, Qualls S, Weiss S et al. Sensitive TSH tests - specificity limitations for screening for thyroid disease in hospitalized patients. *Clin Chem* 1987;33:1391-1396.
93. Stockigt JR. Guidelines for diagnosis and monitoring of thyroid disease: nonthyroidal illness. *Clin Chem* 1996;42:188-92.
94. Nelson JC and Weiss RM. The effects of serum dilution on free thyroxine (T4) concentration in the low T4 syndrome of nonthyroidal illness. *J Clin Endocrinol Metab* 1985;61:239-46.
95. Chopra IJ, Huang TS, Beredo A, Solomon DH, Chua Teco GN. Serum thyroid hormone binding inhibitor in non thyroidal illnesses. *Metabolism* 1986;35:152-9.
96. Wang R, Nelson JC and Wilcox RB. Salsalate administration - a potential pharmacological model of the sick euthyroid syndrome. *J Clin Endocrinol Metab* 1998;83:3095-9.
97. Sapin R, Schliener JL, Kaltenbach G, Gasser F, Christofides N, Roul G et al. Determination of free triiodothyronine by six different methods in patients with non-thyroidal illness and in patients treated with amiodarone. *Ann Clin Biochem* 1995;32:314-24.
98. Docter R, van Toor H, Krenning EP, de Jong M and Hennemann G. Free thyroxine assessed with three assays in sera of patients with nonthyroidal illness and of subjects with abnormal concentrations of thyroxine-binding proteins. *Clin Chem* 1993;39:1668-74.
99. Wilcox RB, Nelson JC and Tomei RT. Heterogeneity in affinities of serum proteins for thyroxine among patients with non-thyroidal illness as indicated by the serum free thyroxine response to serum dilution. *Eur J Endocrinol* 1994;131:9-13.
100. Liewendahl K, Tikanoja S, Mahonen H, Helenius T, Valimaki M and Tallgren LG. Concentrations of iodothyronines in serum of patients with chronic renal failure and other nonthyroidal illnesses: role of free fatty acids. *Clin Chem* 1987;33:1382-6.
101. Sapin R, Schlienger JL, Gasser F, Noel E, Lioure B, Grunenberger F. Intermethod discordant free thyroxine measurements in bone marrow-transplanted patients. *Clin Chem* 2000;46:418-22.
102. Chopra IJ. Simultaneous measurement of free thyroxine and free 3,5,3'-triiodothyronine in undiluted serum by direct equilibrium dialysis/radioimmunoassay: evidence that free triiodothyronine and free thyroxine are normal in many patients with the low triiodothyronine syndrome. *Thyroid* 1998;8:249-57.
103. Hamblin PS, Dyer SA, Mohr VS, Le Grand BA, Lim C-F, Tuxen DB, Topliss DJ and Stockigt JR. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. *J Clin Endocrinol Metab* 1986;62:717-22.
104. Brent GA and Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentrations. *J Clin Endocrinol Metab* 1986;63:1-8.
105. De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. *J Clin Endocrinol Metab* 1999;84:151-64.
106. Burman KD and Wartofsky L. Thyroid function in the intensive care unit setting. *Crit Care Clin* 2001;17:43-57.
107. Behrend EN, Kemppainen RJ and Young DW. Effect of storage conditions on cortisol, total thyroxine and free thyroxine concentrations in serum and plasma of dogs. *J Am Vet Med Assoc* 1998;212:1564-8.
108. Oddie TH, Klein AH, Foley TP and Fisher DA. Variation in values for iodothyronine hormones, thyrotropin and thyroxine binding globulin in normal umbilical-cord serum with season and duration of storage. *Clin Chem* 1979;25:1251-3.
109. Koliakos G, Gaitatzi M and Grammaticos P. Stability of serum TSH concentration after non refrigerated storage. *Minerva Endocrinol* 1999;24:113-5.
110. Waite KV, Maberly GF and Eastman CJ. Storage conditions and stability of thyrotropin and thyroid hormones on filter paper. *Clin Chem* 1987;33:853-5.
111. Levinson SS. The nature of heterophilic antibodies and their role in immunoassay interference. *J Clin Immunoassay* 1992;15:108-15.
112. Norden AGM, Jackson RA, Norden LE, Griffin AJ, Barnes MA and Little JA. Misleading results for immunoassays of serum free thyroxine in the presence of rheumatoid factor. *Clin Chem* 1997;43:957-62.
113. Covinsky M, Laterza O, Pfeifer JD, Farkas-Szallasi T and Scott MG. Lambda antibody to *Escherichia coli* produces false-positive results in multiple immunometric assays. *Clin Chem* 2000;46:1157-61.

114. Martel J, Despres N, Ahnadi CE, Lachance JF, Monticello JE, Fink G, Ardemagni A, Banfi G, Tovey J, Dykes P, John R, Jeffery J and Grant AM. Comparative multicentre study of a panel of thyroid tests using different automated immunoassay platforms and specimens at high risk of antibody interference. *Clin Chem Lab Med* 2000;38:785-93.
115. Howanitz PJ, Howanitz JH, Lamberson HV and Ennis KM. Incidence and mechanism of spurious increases in serum Thyrotropin. *Clin Chem* 1982;28:427-31.
116. Boscato, L. M. and M. C. Stuart. Heterophilic antibodies: a problem for all immunoassays. *Clin Chem* 1988;34:27-33.
117. Kricka LJ. Human anti-animal antibody interference in immunological assays. *Clin Chem* 1999;45:942-56.
118. Sapin R and Simon C. False hyperprolactinemia corrected by the use of heterophilic antibody-blocking agent. *Clin Chem* 2001;47:2184-5.
119. Feldt-Rasmussen U, Petersen PH, Blaabjerg O and Horder M. Long-term variability in serum thyroglobulin and thyroid related hormones in healthy subjects. *Acta Endocrinol (Copenh)* 1980;95:328-34.
120. Browning MCK, Ford RP, Callaghan SJ and Fraser CG. Intra-and interindividual biological variation of five analytes used in assessing thyroid function: implications for necessary standards of performance and the interpretation of results. *Clin Chem* 1986;32:962-6.
121. Lum SM and Nicoloff JT. Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man. *J Clin Invest* 1984;73:570-5.
122. Spencer CA and Wang CC. Thyroglobulin measurement:- Techniques, clinical benefits and pitfalls. *Endocrinol Metab Clin N Amer* 1995;24:841-63.
123. Weeke J and Gundersen HJ. Circadian and 30 minute variations in serum TSH and thyroid hormones in normal subjects. *Acta Endocrinol* 1978;89:659-72.
124. Brabant G, Prank K, Hoang-Vu C and von zur Muhlen A. Hypothalamic regulation of pulsatile thyrotropin secretion. *J Clin Endocrinol Metab* 1991;72:145-50.
125. Fraser CG, Petersen PH, Ricos C and Haeckel R. Proposed quality specifications for the imprecision and inaccuracy of analytical systems for clinical chemistry. *Eur J Clin Chem Biochem* 1992;30:311-7.
126. Rodbard, D. Statistical estimation of the minimal detectable concentration ("sensitivity") for radioligand assays. *Anal Biochem* 1978;90:1-12.
127. Ekins R and Edwards P. On the meaning of "sensitivity". *Clin Chem* 1997;43:1824-31.
128. Fuentes-Arderiu X and Fraser CG. Analytical goals for interference. *Ann Clin Biochem* 1991;28:393-5.
129. Petersen PH, Fraser CG, Westgard JO and Larsen ML. Analytical goal-setting for monitoring patients when two analytical methods are used. *Clin Chem* 1992;38:2256-60.
130. Fraser CG and Petersen PH. Desirable standards for laboratory tests if they are to fulfill medical needs. *Clin Chem* 1993;39:1453-5.
131. Stockl D, Baadenhuijsen H, Fraser CG, Libeer JC, Petersen PH and Ricos C. Desirable routine analytical goals for quantities assayed in serum. Discussion paper from the members of the external quality assessment (EQA) Working Group A on analytical goals in laboratory medicine. *Eur J Clin Chem Clin Biochem* 1995;33:157-69.
132. Plebani M, Giacomini A, Beghi L, de Paoli M, Roveroni G, Galeotti F, Corsini A and Fraser CG. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. *Anticancer Res* 1996;16:2249-52.
133. Browning MC, Bennet WM, Kirkaldy AJ and Jung RT. Intra-individual variation of thyroxin, triiodothyronine and thyrotropin in treated hypothyroid patients: implications for monitoring replacement therapy. *Clin Chem* 1988;34:696-9.
134. Harris EK. Statistical principles underlying analytic goal-setting in clinical chemistry. *Am J Clin Pathol* 1979;72:374-82.
135. Nelson JC and Wilcox RB. Analytical performance of free and total thyroxine assays. *Clin Chem* 1996;42:146-54.
136. Evans SE, Burr WA and Hogan TC. A reassessment of 8-anilino-1-naphthalene sulphonic acid as a thyroxine binding inhibitor in the radioimmunoassay of thyroxine. *Ann Clin Biochem* 1977;14:330-4.
137. Karapitta CD, Sotiroudis TG, Papadimitriou A and Xenakis A. Homogeneous enzyme immunoassay for triiodothyronine in serum. *Clin Chem* 2001;47:569-74.

138. De Brabandere VI, Hou P, Stockl D, Theinpont LM and De Leenheer AP. Isotope dilution-liquid chromatography/electrospray ionization-tandem mass spectrometry for the determination of serum thyroxine as a potential reference method. *Rapid Commun Mass Spectrom* 1998;12:1099-103.
139. Tai SSC, Sniegoski LT and Welch MJ. Candidate reference method for total thyroxine in human serum: Use of isotope-dilution liquid chromatography-mass spectrometry with electrospray ionization. *Clin Chem* 2002;48:637-42.
140. Thienpont LM, Fierens C, De Leenheer AP and Przywara L. Isotope dilution-gas chromatography/mass spectrometry and liquid chromatography/electro-spray ionization-tandem mass spectrometry for the determination of triiodo-L-thyronine in serum. *Rapid Commun Mass Spectrom* 1999;13:1924-31.
141. Sarne DH, Refetoff S, Nelson JC and Linarelli LG. A new inherited abnormality of thyroxine-binding globulin (TBG-San Diego) with decreased affinity for thyroxine and triiodothyronine. *J Clin Endocrinol Metab* 1989;68:114-9.
142. Schussler GC. The thyroxine-binding proteins. *Thyroid* 2000;10:141-9.
143. Beck-Peccoz P, Romelli PB, Cattaneo MG, Faglia G, White EL, Barlow JW et al. Evaluation of free T4 methods in the presence of iodothyronine autoantibodies. *J Clin Endocrinol Metab* 1984;58:736-9.
144. Sakata S, Nakamura S and Miura K. Autoantibodies against thyroid hormones or iodothyronine. *Ann Intern Med* 1985;103:579-89.
145. Despres N and Grant AM. Antibody interference in thyroid assays: a potential for clinical misinformation. *Clin Chem* 1998;44:440-54.
146. Hay ID, Bayer MF, Kaplan MM, Klee GG, Larsen PR and Spencer CA. American Thyroid Association Assessment of Current Free Thyroid Hormone and Thyrotropin Measurements and Guidelines for Future Clinical Assays. *Clin Chem* 1991;37:2002 - 2008.
147. Ekins R. The science of free hormone measurement. *Proc UK NEQAS Meeting* 1998;3:35-59.
148. Wang R, Nelson JC, Weiss RM and Wilcox RB. Accuracy of free thyroxine measurements across natural ranges of thyroxine binding to serum proteins. *Thyroid* 2000;10:31-9.
149. Nelson JC, Wilcox BR and Pandian MR. Dependence of free thyroxine estimates obtained with equilibrium tracer dialysis on the concentration of thyroxine-binding globulin. *Clin Chem* 1992;38:1294-1300.
150. Ekins R. The free hormone hypothesis and measurement of free hormones. *Clin Chem* 1992;38:1289-93.
151. Ekins RP. Ligand assays: from electrophoresis to miniaturized microarrays. *Clin Chem* 1998;44:2015-30.
152. Ekins R. Analytic measurements of free thyroxine. *Clin Lab Med* 1993;13:599-630.
153. Nusynowitz, M. L. Free-thyroxine index. *JAMA* 1975;232:1050.
154. Larsen PR, Alexander NM, Chopra IJ, Hay ID, Hershman JM, Kaplan MM et al. Revised nomenclature for tests of thyroid hormones and thyroid-related proteins in serum. *J Clin Endocrinol Metab* 1987;64:1089-94.
155. Burr WA, Evans SE, Lee J, Prince HP, Ramsden DB. The ratio of thyroxine to thyroxine-binding globulin measurement in the evaluation of thyroid function. *Clin Endocrinol* 1979;11:333-42.
156. Attwood EC and Atkin GE. The T4: TBG ratio: a re-evaluation with particular reference to low and high serum TBG levels. *Ann Clin Biochem* 1982;19:101-3.
157. Szpunar WE, Stoffer SS and DiGiulio W. Clinical evaluation of a thyroxine binding globulin assay in calculating a free thyroxine index in normal, thyroid disease and sick euthyroid patients. *J Nucl Med* 1987;28:1341-3.
158. Nelson JC and Tomei RT. Dependence of the thyroxin/thyroxin-binding globulin (TBG) ratio and the free thyroxin index on TBG concentrations. *Clin Chem* 1989;35:541-4.
159. Sterling K and Brenner MA. Free thyroxine in human serum: Simplified measurement with the aid of magnesium precipitation. *J Clin Invest* 1966;45:153-60.
160. Schulssler GC and Plager JE. Effect of preliminary purification of ¹³¹I-Thyroxine on the determination of free thyroxine in serum. *J Clin Endocrinol* 1967;27:242-50.
161. Nelson JC and Tomei RT. A direct equilibrium dialysis/radioimmunoassay method for the measurement of free thyroxin in undiluted serum. *Clin Chem* 1988;34:1737-44.
162. Tikanoja SH. Ultrafiltration devices tested for use in a free thyroxine assay validated by comparison with equilibrium dialysis. *Scand J Clin Lab Invest* 1990;50:663-9.

163. Ellis SM and Ekins R. Direct measurement by radioimmunoassay of the free thyroid hormone concentrations in serum. *Acta Endocrinol (Suppl)* 1973;177:106-110.
164. Weeke J and Orskov H. Ultrasensitive radioimmunoassay for direct determination of free triiodothyronine concentration in serum. *Scand J Clin Lab Invest* 1975;35:237-44.
165. Surks MI, Hupart KH, Chao P and Shapiro LE. Normal free thyroxine in critical nonthyroidal illnesses measured by ultrafiltration of undiluted serum and equilibrium dialysis. *J Clin Endocrinol Metab* 1988;67:1031-9.
166. Holm SS andreasen L, Hansen SH, Faber J and Staun-Olsen P. Influence of adsorption and deproteination on potential free thyroxine reference methods. *Clin Chem* 2002;48:108-114.
167. Jaume JC, Mendel CM, Frost PH, Greenspan FS, Laughton CW. Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum-free thyroxine concentrations as measured by equilibrium dialysis. *Thyroid* 1996;6:79-83.
168. Stevenson HP, Archbold GP, Johnston P, Young IS, Sheridan B. Misleading serum free thyroxine results during low molecular weight heparin treatment. *Clin Chem* 1998;44:1002-7.
169. Laji K, Rhidha B, John R, Lazarus J and Davies JS. Artifactual elevations in serum free thyroxine and triiodothyronine concentrations during heparin therapy. *QJM* 2001;94:471-3.
170. Lim CF, Bai Y, Topliss DJ, Barlow JW and Stockigt JR. Drug and fatty acid effects on serum thyroid hormone binding. *J Clin Endocrinol Metab* 1988;67:682-8.
171. Czako G., M. H. Zweig, C. Benson and M. Ruddel. On the albumin-dependence of measurements of free thyroxin. II Patients with non-thyroidal illness. *Clin Chem* 1987;33:87-92.
172. Csako G, Zweig MH, Glickman J, Ruddel M and K. J. Direct and indirect techniques for free thyroxin compared in patients with nonthyroidal illness. II. Effect of prealbumin, albumin and thyroxin-binding globulin. *Clin Chem* 1989;35:1655-62.
173. Csako G, Zweig MH, Glickman J, Kestner J and Ruddel M. Direct and indirect techniques for free thyroxin compared in patients with nonthyroidal illness. I. Effect of free fatty acids. *Clin Chem* 1989;35:102-9.
174. Ross HA and Benraad TJ. Is free thyroxine accurately measurable at room temperature? *Clin Chem* 1992;38:880-6.
175. Van der Sluijs Veer G, Vermes I, Bonte HA and Hoorn RJK. Temperature effects on Free Thyroxine Measurement: Analytical and Clinical Consequences. *Clin Chem* 1992;38:1327-31.
176. Fisher DA. The hypothyroxinemia of prematurity. *J Clin Endocrinol Metab* 1997;82:1701-3.
177. Stockigt JR, Stevens V, White EL and Barlow JW. Unbound analog radioimmunoassays for free thyroxin measure the albumin-bound hormone fraction. *Clin Chem* 1983;29:1408-10.
178. Aravelo G. Prevalence of familial dysalbuminemic hyperthyroxinemia in serum samples received for thyroid testing. *Clin Chem* 1991;37:1430-1.
179. Sapin R and Gasser F. Anti-solid phase antibodies interfering in labeled-antibody assays for free thyroid hormones. *Clin Chem* 1995;45:1790-1.
180. Inada M and Sterling K. Thyroxine transport in thyrotoxicosis and hypothyroidism. *J Clin Invest* 1967;46:1442-50.
181. Lueprasitsakul W, Alex S, Fang SL, Pino S, Irmischer K, Kohrle J et al. Flavonoid administration immediately displaces thyroxine (T4) from serum transthyretin, increases serum free T4 and decreases serum thyrotropin in the rat. *Endocrinol* 1990;126:2890-5.
182. Stockigt JR, Lim CF, Barlow J, Stevens V, Topliss DJ, Wynne KN. High concentrations of furosemide inhibit plasma binding of thyroxine. *J Clin Endocrinol Metab* 1984;59:62-6.
183. Hawkins RC. Furosemide interference in newer free thyroxine assays. *Clin Chem* 1998;44:2550-1.
184. Wang R, Nelson JC and Wilcox RB. Salsalate and salicylate binding to and their displacement of thyroxine from thyroxine-binding globulin, transthyrin and albumin. *Thyroid* 1999;9:359-64.
185. Munro SL, Lim C-F, Hall JG, Barlow JW, Craik DJ, Topliss DJ and Stockigt JR. Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin. *J Clin Endocrinol Metab* 1989;68:1141-7.
186. Stockigt JR, Lim C-F, Barlow JW and Topliss DJ. 1997. *Thyroid hormone transport*. Springer Verlag, Heidelberg. 119 pp.
187. Surks MI and Defesi CR. Normal free thyroxine concentrations in patients treated with phenytoin or carbamazepine: a paradox resolved. *JAMA* 1996;275:1495-8.

188. Ross HA. A dialysis method for the measurement of free iodothyronine and steroid hormones in blood. *Experientia* 1978;34:538-9.
189. Sapin R. Serum thyroxine binding capacity-dependent bias in five free thyroxine immunoassays: assessment with serum dilution experiments and impact on diagnostic performance. *Clin Biochem* 2001;34:367-71.
190. Law LK, Cheung CK and Swaminathan R. Falsely high thyroxine results by fluorescence polarization in sera with high background fluorescence. *Clin Chem* 1988;34:1918.
191. Kricka LJ. Interferences in Immunoassay - still a threat. *Clin Chem* 2000;46:1037-8.
192. McBride JH, Rodgerson DO and Allin RE. Choriogonadotrophin interference in a sensitive assay for Thyrotropin. *Clin Chem* 1987;33:1303-4.
193. Ritter D, Stott R, Grant N and Nahm MH. Endogenous antibodies that interfere with Thyroxine fluorescence polarization assay but not with radioimmunoassay or EMIT. *Clin Chem* 1993;39:508-11.
194. DeGroot LJ, Larsen PR, Refetoff S and Stanbury JB. *The Thyroid and its Diseases*. Fifth Edition, 1984; John Wiley & Sons, Inc., New York:266-7.
195. Beck-Peccoz P, Amr S, Menezes-Ferreira NM, Faglia G and Weintraub BD. Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism: effect of treatment with thyrotropin-releasing hormone. *N Engl J Med* 1985;312:1085-90.
196. Beck-Peccoz P and Persani L. Variable biological activity of thyroid-stimulating hormone. *Eur J Endocrinol* 1994;131:331-40.
197. Persani L, Ferretti E, Borgato S, Faglia G and Beck-Peccoz P. Circulating thyrotropin bioactivity in sporadic central hypothyroidism. *J Clin Endocrinol Metab* 2000;85:3631-5.
198. Rafferty B and Gaines Das R. Comparison of pituitary and recombinant human thyroid-stimulating hormone (rhTSH) in a multicenter collaborative study: establishment of the first World Health Organization reference reagent for rhTSH. *Clin Chem* 1999;45:2207-15.
199. Persani L, Borgato S, Romoli R, Asteria C, Pizzocaro A and Beck-Peccoz P. Changes in the degree of sialylation of carbohydrate chains modify the biological properties of circulating thyrotropin isoforms in various physiological and pathological states. *J Clin Endocrinol Metab* 1998;83:2486-92.
200. Gershengorn MC and Weintraub BD. Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of "inappropriate secretion of TSH". *J Clin Invest* 1975;56:633-42.
201. Faglia G, Beck-Peccoz P, Piscitelli G and Medri G. Inappropriate secretion of thyrotropin by the pituitary. *Horm Res* 1987;26:79-99.
202. Spencer CA, Takeuchi M and Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. *Clinical Chemistry* 1996;42:141-145.
203. Laurberg P. Persistent problems with the specificity of immunometric TSH assays. *Thyroid* 1993;3:279-83.
204. Spencer CA, Schwarzbein D, Guttler RB, LoPresti JS and Nicoloff JT. TRH stimulation test responses employing third and fourth generation TSH assays. *J Clin Endocrinol Metab* 1993;76:494-498.
205. Vogeser M, Weigand M, Fraunberger P, Fischer H and Cremer P. Evaluation of the ADVIA Centaur TSH-3 assay. *Clin Chem Lab Med* 2000;38:331-4.
206. Spencer CA, Takeuchi M, Kazarosyn M, MacKenzie F, Beckett GJ and Wilkinson E. Interlaboratory/intermethod differences in functional sensitivity of immunometric assays for thyrotropin (TSH): impact on reliability of measurement of subnormal concentration. *Clin Chem* 1995;41:367-74.
207. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T and Smith PA. The spectrum of thyroid disease in a community: the Wickham survey. *Clin Endocrinol* 1977;7:481-93.
208. Rago T, Chiovato L, Grasso L, Pinchera A and Vitti P. Thyroid ultrasonography as a tool for detecting thyroid autoimmune diseases and predicting thyroid dysfunction in apparently healthy subjects. *J Endocrinol Invest* 2001;24:763-9.
209. Hershman JM and Pittman JA. Utility of the radioimmunoassay of serum thyrotropin in man. *Ann Intern Med* 1971;74:481-90.
210. Becker DV, Bigos ST, Gaitan E, Morris JC, Rallison ML, Spencer CA, Sugawara M, Middlesworth LV and Wartofsky L. Optimal use of blood tests for assessment of thyroid function. *JAMA* 1993;269:2736.

211. Canaris GJ, Manowitz NR, Mayor G and Ridgway EC. The Colorado Thyroid Disease Prevalence Study. *Arch Intern Med* 2000;160:19-27.
212. Skamene A and Patel YC. Infusion of graded concentrations of somatostatin in man: pharmacokinetic and differential inhibitory effects on pituitary and islet hormones. *Clin Endocrinol* 1984;20:555-64.
213. Berghout A, Wiersinga WM, Smits NJ and Touber JL. Interrelationships between age, thyroid volume, thyroid nodularity and thyroid function in patients with sporadic nontoxic goiter. *Am J Med* 1990;89:602-8.
214. Parle JV, Franklyn JA, Cross KW, Jones SC and Sheppard MC. Prevalence and follow-up of abnormal thyrotropin (TSH) concentrations in the elderly in the United Kingdom. *Clin Endocrinol* 1991;34:77-83.
215. Danese D, Sciacchitano S, Farsetti A, Andreoli M and Pontecorvi A. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. *Thyroid* 1998;8:15-21.
216. McDermott MT and Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. *J Clin Endocrinol Metab* 2001;86:4585-90.
217. Chu JW and Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. *J Clin Endocrinol Metab* 2001;86:4591-9.
218. Lewis GF, Alessi CA, Imperial JG and Refetoff S. Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression. *JCEM* 1991;73:843-9.
219. Pearce CJ and Himsworth RL. Total and free thyroid hormone concentrations in patients receiving maintenance replacement treatment with thyroxine. *Br Med J* 1984;288:693-5.
220. Fish LH, Schwarz HL, Cavanaugh MD, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism and bioavailability of levothyroxine in the treatment of hypothyroidism. *N Engl J Med* 1987;316:764-70.
221. Sawin CT, Herman T, Molitch ME, London MH and Kramer SM. Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. *Amer J Med* 1983;75:206-9.
222. Davis FB, LaMantia RS, Spaulding SW, Wemann RE and Davis PJ. Estimation of a physiologic replacement dose of levothyroxine in elderly patients with hypothyroidism. *Arch Intern Med* 1984;144.
223. Arafah BM. Estrogen therapy may necessitate an increase in thyroxine dose for hypothyroidism. *NEJM* 2001;344:1743-9.
224. Scheithauer BW, Kovacs K, Randall RV and Ryan N. Pituitary gland in hypothyroidism. Histologic and immunocytologic study. *Arch Pathol Lab Med* 1985;109:499-504.
225. Ain KB, Pucino F, Shiver T and Banks SM. Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. *Thyroid* 1993;3:81-5.
226. Chorazy PA, Himelhoch S, Hopwood NJ, Greger NG and Postellon DC. Persistent hypothyroidism in an infant receiving a soy formula: case report and review of the literature. *Pediatrics* 1995;96:148-50.
227. Dulgeroff AJ and Hershman JM. Medical therapy for differentiated thyroid carcinoma. *Endocrinol Rev* 1994;15:500-15.
228. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J and Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. *J Clin Endocrinol Metab* 1996;81:4318-23.
229. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T and Maxon HR 3rd. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National thyroid Cancer Treatment Cooperative Registry. *Thyroid* 1999;8:737-44.
230. Hurley DL and Gharib H. Evaluation and management of multinodular goiter. *Otolaryngol Clin North Am* 1996;29:527-40.
231. Bayer MF, Macoviak JA and McDougall IR. Diagnostic performance of sensitive measurements of serum thyrotropin during severe nonthyroidal illness: Their role in the diagnosis of hyperthyroidism. *Clin Chem* 1987;33:2178-84.
232. Lum SM, Kaptein EM and Nicoloff JT. Influence of nonthyroidal illnesses on serum thyroid hormone indices in hyperthyroidism. *West J Med* 1983;138:670-5.
233. Faglia G, Bitensky L, Pinchera A, Ferrari C, Paracchi A, Beck-Peccoz P, Ambrosi B and Spada A. Thyrotropin secretion in patient with central hypothyroidism: Evidence for reduced biological activity of immunoreactive thyrotropin. *J Clin Endocrinol Metab* 1979;48:989-98.

234. Faglia G, Beck-Peccoz P, Ballabio M and Nava C. Excess of beta-subunit of thyrotropin (TSH) in patients with idiopathic central hypothyroidism due to the secretion of TSH with reduced biological activity. *J Clin Endocrinol Metab* 1983;56:908-14.
235. Faglia G. The clinical impact of the thyrotropin-releasing hormone test. *Thyroid* 1998;8:903-8.
236. Trejbal D, Sulla I, Trejbalova L, Lazurova I, Schwartz P and Machanova Y. Central hypothyroidism - various types of TSH responses to TRH stimulation. *Endocr Regul* 1994;28:35-40.
237. Faglia G, Ferrari C, Paracchi A, Spada A and Beck-Peccoz P. Triiodothyronine response to thyrotropin releasing hormone in patients with hypothalamic-pituitary disorders. *Clin Endocrinol* 1975;4:585-90.
238. Horimoto M, Nishikawa M, Ishihara T, Yoshikawa N, Yoshimura M and Inada M. Bioactivity of thyrotropin (TSH) in patients with central hypothyroidism: comparison between in vivo 3,5,3'-triiodothyronine response to TSH and in vitro bioactivity of TSH. *J Clin Endocrinol Metab* 1995;80:1124-8.
239. Refetoff S, Weiss RE and Usala SJ. The syndromes of resistance to thyroid hormone. *Endocr Rev* 1993;14:348-99.
240. Weiss RE, Hayashi Y, Nagaya T, Petty KJ, Murata Y, Tunca H, Seo H and Refetoff S. Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptors alpha or beta genes may be due to a defective co-factor. *J Clin Endocrinol Metab* 1996;81:4196-203.
241. Snyder D, Sesser D, Skeels M et al. Thyroid disorders in newborn infants with elevated screening T4. *Thyroid* 1997;7 (Suppl 1):S1-29 (abst).
242. Refetoff S. 2000. Resistance to Thyroid Hormone. *In* The Thyroid. Braverman LE and Utiger RD, editor. Lippincott Williams & Wilkins, Philadelphia. 1028-43.
243. Beck-Peccoz P and Chatterjee VKK. The variable clinical phenotype in thyroid hormone resistance syndrome. *Thyroid* 1994;4:225-32.
244. Persani L, Asteria C, Tonacchera M, Vitti P, Krishna V, Chatterjee K and Beck-Peccoz P. Evidence for the secretion of thyrotropin with enhanced bioactivity in syndromes of thyroid hormone resistance. *J Clin Endocrinol Metab* 1994;78:1034-9.
245. Same DH, Sobieszcyk S, Ain KB and Refetoff S. Serum thyrotropin and prolactin in the syndrome of generalized resistance to thyroid hormone: responses to thyrotrophin-releasing hormone stimulation and triiodothyronine suppression. *J Clin Endocrinol Metab* 1990;70:1305-11.
246. Ercan-Fang S, Schwartz HL, Mariash CN and Oppenheimer JH. Quantitative assessment of pituitary resistance to thyroid hormone from plots of the logarithm of thyrotropin versus serum free thyroxine index. *J Clin Endocrinol Metab* 2000;85:2299-303.
247. Safer JD, Colan SD, Fraser LM and Wondisford FE. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma. *Thyroid* 2001;11:281-91.
248. Marcocci C and Chiovato L. 2000. Thyroid -directed antibodies. *In* Thyroid. B. L. a. U. RD, editor. Lippincott Williams and Wilkins, Philadelphia. 414-31.
249. Chiovato L, Bassi P, Santini F, Mammoli C, Lapi P, Carayon P and Pinchera A. Antibodies producing complement-mediated thyroid cytotoxicity in patients with atrophic or goitrous autoimmune thyroiditis. *J Clin Endocrinol Metab* 1993;77:1700-5.
250. Guo J, Jaume JC, Rapoport B and McLachlan SM. Recombinant thyroid peroxidase-specific Fab converted to immunoglobulin G (IgG)molecules: evidence for thyroid cell damage by IgG1, but not IgG4, autoantibodies. *J Clin Endocrinol Metab* 1997;82:925-31.
251. Doullay F, Ruf J, Codaccioni JL and Carayon P. Prevalence of autoantibodies to thyroperoxidase in patients with various thyroid and autoimmune diseases. *Autoimmunity* 1991;9:237-44.
252. Radetti G, Persani L, Moroder , Cortelazzi D, Gentili L, Beck-Peccoz P. Transplacental passage of anti-thyroid autoantibodies in a pregnant woman with auto-immune thyroid disease. *Prenatal Diagnosis* 1999;19:468-71.
253. Heithorn R, Hauffa BP and Reinwein D. Thyroid antibodies in children of mothers with autoimmune thyroid disorders. *Eur J Pediatr* 1999;158:24-8.
254. Feldt-Rasmussen. Anti-thyroid peroxidase antibodies in thyroid disorders and non thyroid autoimmune diseases. *Autoimmunity* 1991;9:245-51.
255. Mariotti S, Chiovato L, Franceschi C and Pinchera A. Thyroid autoimmunity and aging. *Exp Gerontol* 1999;33:535-41.

256. Ericsson UB, Christensen SB and Thorell JI. A high prevalence of thyroglobulin autoantibodies in adults with and without thyroid disease as measured with a sensitive solid-phase immunosorbent radioassay. *Clin Immunol Immunopathol* 1985;37:154-62.
257. Feldt-Rasmussen U, Hoier-Madsen M, Rasmussen NG, Hegedus L and Hornnes P. Anti-thyroid peroxidase antibodies during pregnancy and postpartum. Relation to postpartum thyroiditis. *Autoimmunity* 1990;6:211-4.
258. Premawardhana LD, Parkes AB, AMMARI F, John R, Darke C, Adams H and Lazarus JH. Postpartum thyroiditis and long-term thyroid status: prognostic influence of Thyroid Peroxidase Antibodies and ultrasound echogenicity. *J Clin Endocrinol Metab* 2000;85:71-5.
259. Johnston AM and Eagles JM. Lithium-associated clinical hypothyroidism. Prevalence and risk factors. *Br. J Psychiatry* 1999;175:336-9.
260. Bell TM, Bansal AS, Shorthouse C, Sandford N and Powell EE. Low titre autoantibodies predict autoimmune disease during interferon alpha treatment of chronic hepatitis C. *J Gastroenterol Hepatol* 1999;14:419-22.
261. Ward DL and Bing-You RG. Autoimmune thyroid dysfunction induced by interfereon-alfa treatment for chronic hepatitis C: screening and monitoring recommendations. *Endoc Pract* 2001;7:52-8.
262. Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, Sorvillo F, Caporaso N and Amato G. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. *J Clin Endocrinol Metab* 2001;86:1925-9.
263. Feldt-Rasmussen U, Schleusener H and Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. *J Clin Endocrinol Metab* 1994;78:98-103.
264. Estienne V, Duthoit C, Di Costanzo, Lejeune PJ, Rotondi M, Kornfeld S et al. Multicenter study on TGPO autoantibodies prevalence in various thyroid and non-thyroid diseases: relationships with thyroglobulin and thyroperoxidase autoantibody parameters. *Eur J Endocrinol* 1999;141:563-9.
265. Czarnocka B, Ruf J, Ferrand M et al. Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid diseases. *FEBS Lett* 1985;190:147-52.
266. Mariotti S, Caturegli P, Piccolo P, Barbesino G and Pinchera A. Antithyroid peroxidase autoantibodies in thyroid diseases. *J Clin Endocrinol Metab* 1990;71:661-9.
267. Rubello D, Pozzan GB, Casara D, Girelli ME, Boccato s, Rigon F, Baccichetti C, Piccolo M, Betterle C and Busnardo B. Natural course of subclinical hypothyroidism in Down's syndrome: prospective study results and therapeutic considerations. *J Endocrinol Invest* 1995;18:35-40.
268. Karlsson B, Gustafsson J, Hedov G, Ivarsson SA and Anneren G. Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. *Arch Dis Child* 1998;79:242-5.
269. Bussen S, Steck T and Dietl J. Increased prevalence of thyroid antibodies in euthyroid women with a history of recurrent in-vitro fertilization failure. *Hum Reprod* 2000;15:545-8.
270. Phan GQ, Attia P, Steinberg SM, White DE and Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. *J Clin Oncol* 2001;19:3477-82.
271. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E and Zaffaroni M. Thyroid function and autoimmunity during interferon-Beta-1b Treatment: a Multicenter Prospective Study. *J Clin Endocrinol Metab* 2001;86:3525-32.
272. Roti E, Minelli R, Giuberti T, Marchelli C, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri TM and Braverman LE. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. *Am J Med* 1996;101:482-7.
273. Ruf J, Carayon P and Lissitzky S. Various expression of a unique anti-human thyroglobulin antibody repertoire in normal state and autoimmune disease. *Eur J Immunol* 1985;15:268-72.
274. Ruf J, Toubert ME, Czarnocka B, Durand-Gorde JM, Ferrand M, Carayon P. Relationship between immunological structure and biochemical properties of human thyroid peroxidase. *Endocrinol* 1989;125:1211-8.
275. Feldt-Rasmussen U and Rasmussen A K. Serum thyroglobulin (Tg) in presence of thyroglobulin autoantibodies (TgAb). Clinical and methodological relevance of the interaction between Tg and TgAb in vivo and in vitro. *J Endocrinol Invest* 1985;8:571-6.

276. Spencer CA, Wang C, Fatemi S, Guttler RB, Takeuchi M and Kazarosyan M. Serum Thyroglobulin Autoantibodies: Prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 1998;83:1121-7.
277. Pacini F, Mariotti S, Formica N and Elisei R. Thyroid autoantibodies in thyroid cancer: Incidence and relationship with tumor outcome. *Acta Endocrinol* 1988;119:373-80.
278. Rubello D, Casara D, Girelli ME, Piccolo M and Busnardo B. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. *J Nucl Med* 1992;33:1478-80.
279. Nordyke RA, Gilbert FI, Miyamoto LA and Fleury KA. The superiority of antimicrosomal over antithyroglobulin antibodies for detecting Hashimoto's thyroiditis. *Arch Intern Med* 1993;153:862-5.
280. Di Cerbo A, Di Paola R, Menzaghi C, De Filippis V, Tahara K, Corda D et al. Graves' immunoglobulins activate phospholipase A2 by recognizing specific epitopes on the thyrotropin receptor. *J Clin Endocrinol Metab* 1999;84:3283-92.
281. Kung AWC, Lau KS and Kohn LD. Epitope mapping of TSH Receptor-blocking antibodies in Graves' disease that appear during pregnancy. *J Clin Endocrinol Metab* 2001;86:3647-53.
282. Ueta Y, Fukui H, Murakami M, Yamanouchi Y, Yamamoto R, Murao A et al. Development of primary hypothyroidism with the appearance of blocking-type antibody to thyrotropin receptor in Graves' disease in late pregnancy. *Thyroid* 1999;9:179-82.
283. Gupta MK. Thyrotropin-receptor antibodies in thyroid diseases: advances in detection techniques and clinical application. *Clin Chem Acta* 2000;293:1-29.
284. Kung AW, Lau KS and Kohn LD. Characterization of thyroid-stimulating blocking antibodies that appeared during transient hypothyroidism after radioactive iodine therapy. *Thyroid* 2000;10:909-17.
285. Filetti S, Foti D, Costante G and Rapoport B. Recombinant human thyrotropin (TSH) receptor in a radioreceptor assay for the measurement of TSH receptor antibodies. *J Clin Endocrinol Metab* 1991;72:1096-101.
286. Adams DD and Purves HD. Abnormal responses in the assay of thyrotropin. *Proc Univ Otago Med Sch* 1956;34:11-12.
287. Morgenthaler NG. New assay systems for thyrotropin receptor antibodies. *Current Opinion Endocrinol Diabetes* 1998;6:251-60.
288. Kamijo K, Nagata A and Sato Y. Clinical significance of a sensitive assay for thyroid-stimulating antibodies in Graves' disease using polyethylene glycol at high concentration and porcine thyroid cells. *Endocrinol J* 1999;46:397-403.
289. Takasu N, Yamashiro K, Ochi Y, Sato Y, Nagata A, Komiya I et al. TSBAbs (TSH-Stimulation Blocking Antibody) and TSABs (Thyroid Stimulating Antibody) in TSBAbs-positive patients with hypothyroidism and Graves' patients with hyperthyroidism. *Horm Metab Res* 2001;33:232-7.
290. Costagliola S, Swillens S, Niccoli P, Dumont JE, Vassart G and Ludgate M. Binding assay for thyrotropin receptor autoantibodies using the recombinant receptor protein. *J Clin Endocrinol Metab* 1992;75:1540-44.
291. Morgenthaler NG, Hodak K, Seissler J, Steinbrenner H, Pampel I, Gupta M et al. Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: a comparison to radioreceptor assay and thyroid stimulating bioassay. *Thyroid* 1999;9:466-75.
292. Akamizu T, Inoue D, Kosugi S, Kohn LD and Mori T. Further studies of amino acids (268-304) in thyrotropin (TSH)-lutropin/chorionic gonadotropin (LH/CG) receptor chimeras: Cysteine-301 is important in TSH binding and receptor tertiary structure. *Thyroid* 1994;4:43-8.
293. Grasso YZ, Kim MR, Faiman C, Kohn LD, Tahara K and Gupta MK. Epitope heterogeneity of thyrotropin-blocking antibodies in Graves' patients as detected with wild-type versus chimeric thyrotropin receptors. *Thyroid* 1999;9:521-37.
294. Kim WB, Chung HK, Lee HK, Kohn LD, Tahara K and Cho BY. Changes in epitopes for thyroid stimulation antibodies in Graves' disease sera during treatment of hyperthyroidism: Therapeutic implications. *J Clin Endocrinol Metab* 1997;82:1953-9.
295. Shewring G and Smith BR. An improved radioreceptor assay for TSH receptor. *Methods Enzymol* 1982;17:409-17.

296. Costagliola S, Morgenthaler NG, Hoermann R, Badenhop K, Struck J, Freitag D, Poertl S, Weglohner W, Hollidt JM, Quadbeck B, Dumont JE, Schumm-Draeger PM, Bergmann A, Mann K, Vassart G and Usadel KH. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. *J Clin Endocrinol Metab* 1999;84:90-7.
297. Schott M, Feldkamp J, Bathan C, Fritzen R, Scherbaum WA and Seissler J. Detecting TSH-Receptor antibodies with the recombinant TBII assay: Technical and Clinical evaluation. *32* 2000;:429-35.
298. Feldt-Rasmussen U. Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin and thyrotropin receptor. *Clin Chem* 1996;42:160-3.
299. Giovanella L, Ceriani L and Garancini S. Clinical applications of the 2nd. generation assay for anti-TSH receptor antibodies in Graves' disease. Evaluation in patients with negative 1st. generation test. *Clin Chem Lab med* 2001;39:25-8.
300. Momotani N, Noh JY, Ishikawa N and Ito K. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. *J Clin Endocrinol Metab* 1997;82:3633-6.
301. Brown RS, Bellisario RL, Botero D, Fournier L, Abrams CA, Cower ML et al. Incidence of transient congenital hypothyroidism due to maternal thyrotropin receptor-blocking antibodies in over one million babies. *J Clin Endocrinol Metab* 1996;81:1147-51.
302. Gerding MN, van der Meer Jolanda WC, Broenink M, Bakker O, W. WM and Prummel MF. Association of thyrotropin receptor antibodies with the clinical features of Graves' ophthalmopathy. *Clin Endocrinol* 2000;52:267-71.
303. Bartelena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E et al. Relation between therapy for hyperthyroidism and the course of Graves' disease. *N Engl J Med* 1998;338:73-8.
304. Bech K. Immunological aspects of Graves' disease and importance of thyroid stimulating immunoglobulins. *Acta Endocrinol (Copenh) Suppl* 1983;103:5-38.
305. Feldt-Rasmussen U. Serum thyroglobulin and thyroglobulin autoantibodies in thyroid diseases et al. *lergy* 1983;38:369-87.
306. Nygaard B, Metcalfe RA, Phipps J, Weetman AP and Hegedus L. Graves' disease and thyroid-associated ophthalmopathy triggered by 131I treatment of non-toxic goitre. *J Endocrinol Invest* 1999;22:481-5.
307. Ericsson UB, Tegler L, Lennquist S, Christensen SB, Stahl E and Thorell JI. Serum thyroglobulin in differentiated thyroid carcinoma. *Acta Chir Scand* 1984;150:367-75.
308. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD and Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. *J Clin Endocrinol Metab* 1999;84:3877-85.
309. Spencer CA, LoPresti JS, Fatemi S and Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum Thyroglobulin measurement. *Thyroid* 1999;9:435-41.
310. Schlumberger M, C. P., Fragu P, Lumbroso J, Parmentier C and Tubiana M. Circulating thyrotropin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels. *J Clin Endocrinol Metab* 1980;51:513-9.
311. Pacini F, Fugazzola L, Lippi F, Ceccarelli C, Centoni R, Miccoli P, Elisei R and Pinchera A. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. *J Clin Endocrinol Metab* 1992;74:1401-4.
312. Spencer CA, Takeuchi M and Kazarosyan M. Current Status and Performance Goals for Serum Thyroglobulin Assays. *Clin Chem* 1996;42:164-73.
313. Feldt-Rasmussen U and Schlumberger M. European interlaboratory comparison of serum thyroglobulin measurement. *J Endocrinol Invest* 1988;11:175-81.
314. Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P et al. Human thyroglobulin reference material (CRM 457) 2nd part: Physicochemical characterization and certification. *Ann Biol Clin* 1996;54:343-348.
315. Schlumberger M J. Papillary and Follicular Thyroid Carcinoma. *NEJM* 1998;338:297-306.
316. Hjiyiannakis P, Mundy J and Harmer C. Thyroglobulin antibodies in differentiated thyroid cancer. *Clin Oncol* 1999;11:240-4.
317. Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies. *Clin Chem* 1996;42:661-3.

318. Massart C and Maugendre D. Importance of the detection method for thyroglobulin antibodies for the validity of thyroglobulin measurements in sera from patients with Graves' disease. *Clin Chem* 2002;48:102-7.
319. Mariotti S, Barbesino G, Caturegli P, Marino M, Manetti L, Pacini F, Centoni R and Pinchera A. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? *J Clin Endocrinol Metab* 1995;80:468-72.
320. Black EG and Hoffenberg R. Should one measure serum thyroglobulin in the presence of anti-thyroglobulin antibodies? *Clin Endocrinol* 1983;19:597-601.
321. Schneider AB and Pervos R. Radioimmunoassay of human thyroglobulin: effect of antithyroglobulin autoantibodies. *J Clin Endocrinol Metab* 1978;47:126-37.
322. Spencer CA, Platler BW and Nicoloff JT. The effect of 125-I thyroglobulin tracer heterogeneity on serum Tg RIA measurement. *Clin Chem Acta* 1985;153:105-115.
323. Bugalho MJ, Domingues RS, Pinto AC, Garrao A, Catarino AL, Ferreira T, Limbert E and Sobrinho L. Detection of thyroglobulin mRNA transcripts in peripheral blood of individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. *Eur J Endocrinol* 2001;145:409-13.
324. Bellantone R, Lombardi CP, Bossola M, Ferrante A, Princi P, Boscherini M et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrence varies according to the histologic type: results of a prospective study. *Cancer* 2001;92:2273-9.
325. Bojunga J, Roddiger S, Stanisch M, Kusterer K, Kurek R, Renneberg H, Adams S, Lindhorst E, Usadel KH and Schumm-Draeger PM. Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR. *Br J Cancer* 2000;82:1650-5.
326. Smith B, Selby P, Southgate J, Pittman K, Bradley C and Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. *Lancet* 1991;338:1227-9.
327. Luppi M, Morselli M, Bandieri E, Federico M, Marasca R, Barozzi P, Ferrari MG, Savarino M, Frassoldati A and Torelli G. Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. *Ann Oncol* 1996;7:619-24.
328. Ghossein RA and Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. *Eur J Cancer* 2000;36:1681-94.
329. Ditkoff BA, Marvin MR, Yemul S, Shi YJ, Chabot J, Feind C et al. Detection of circulating thyroid cells in peripheral blood. *Surgery* 1996;120:959-65.
330. Arturi F, Russo D, Giuffrida D et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. *J Clin Endocrinol Metab* 1997;82:1638-41.
331. Ringel MD, Balducci-Silano PL, Anderson JS, Spencer CA, Silverman J, Sparling YH, Francis GL, Burman KD, Wartofsky L, Ladenson PW, Levine MA and Tuttle RM. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. *J Clin Endocrinol Metab* 1998;84:4037-42.
332. Biscolla RP, Cerutti JM and Maciel RM. Detection of recurrent thyroid cancer by sensitive nested reverse transcription-polymerase chain reaction of thyroglobulin and sodium/iodide symporter messenger ribonucleic acid transcripts in peripheral blood. *J Clin Endocrinol Metab* 2000;85:3623-7.
333. Takano T, Miyauchi A, Yoshida H, Hasegawa Y, Kuma K and Amino N. Quantitative measurement of thyroglobulin mRNA in peripheral blood of patients after total thyroidectomy. *Br J Cancer* 2001;85:102-6.
334. Chelly J, Concordet JP, Kaplan JC and Kahn A. Illegitimate transcription: transcription of any gene in any cell type. *Proc Natl Acad Sci USA* 1989;86:2617-21.
335. Premawardhana LDKE, Phillips DW, Prentice LM and Smith BR. Variability of serum thyroglobulin levels is determined by a major gene. *Clin Endocrinol* 1994;41:725-9.
336. Bertelsen JB and Hegedus L. Cigarette smoking and the thyroid. *Thyroid* 1994;4:327-31.
337. Knudsen N, Bulow I, Jorgensen T, Perrild H, Oversen L and Laurberg P. Serum Tg - a sensitive marker of thyroid abnormalities and iodine deficiency in epidemiological studies. *J Clin Endocrinol Metab* 2001;86:3599-603.

338. Van den Briel T, West CE, Hautvast JG, Vulsma T, de Vijlder JJ and Ategbo EA. Serum thyroglobulin and urinary iodine concentration are the most appropriate indicators of iodine status and thyroid function under conditions of increasing iodine supply in schoolchildren in Benin. *J Nutr* 2001;131:2701-6.
339. Gardner DF, Rothman J and Utiger RD. Serum thyroglobulin in normal subjects and patients with hyperthyroidism due to Graves' disease: effects of T3, iodide, 131I and antithyroid drugs. *Clin Endocrinol* 1979;11:585-94.
340. Feldt-Rasmussen U, Petersen PH, Date J and Madsen CM. Serum thyroglobulin in patients undergoing subtotal thyroidectomy for toxic and nontoxic goiter. *J Endocrinol Invest* 1982;5:161-4.
341. Hocevar M, Auersperg M and Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. 1997;23:208-10.
342. Cohen JH, Ingbar SH and Braverman LE. Thyrotoxicosis due to ingestion of excess thyroid hormone. *Endocrine Rev* 1989;10:113-24.
343. Mitchell ML and Hermos RJ. Measurement of thyroglobulin in newborn screening specimens from normal and hypothyroid infants. *Clin Endocrinol* 1995;42:523-7.
344. Smallridge RC, De Keyser FM, Van Herle AJ, Butkus NE and Wartofsky L. Thyroid iodine content and serum thyroglobulin: clues to the natural history of destruction-induced thyroiditis. *J Clin Endocrinol Metab* 1986;62:1213-9.
345. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M and Pinchera A. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2001;86:5686-90.
346. Cobin RH. 1992. Medullary carcinoma of the thyroid. *In* Malignant tumors of the thyroid: clinical concepts and controversies. S. D. Cobin RH, editor. Springer-Verlag,, New York. 112-41.
347. Dunn JT. When is a thyroid nodule a sporadic medullary carcinoma? *J Clin Endocrinol Metab* 1994;78:824-5.
348. Pacini F, Fontanelli M, Fugazzola L and et. al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1994;78:826-9.
349. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* 1993;363:458-60.
350. Hofstra RM, Landvaster RM, Ceccherini I et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. *Nature* 1994;367:375-6.
351. Heyningen van V. One gene-four syndromes. *Nature* 1994;367:319-20.
352. Becker KL, Nylen ES, Cohen R and Snider RH. Calcitonin: structure, molecular biology and actions. *In*: J.P. Belezianian, L.E. Raisz, G.A.Rodan eds. Principle of bone biology, Academic Press, San Diego 1996;:471-4.
353. Motte P, Vauzelle P, Gardet P, Ghillani P, Caillou B, Parmentier C et al. Construction and clinical validation of a sensitive and specific assay for mature calcitonin using monoclonal anti-peptide antibodies. *Clin Chim Acta* 1988;174:35-54.
354. Zink A, Blind E and Raue F. Determination of serum calcitonin by immunometric two-site assays in normal subjects and patients with medullary thyroid carcinoma. *Eur J Clin Chem Biochem* 1992;30:831-5.
355. Engelbach M, Gorges R, Forst T, Pfutzner A, Dawood R, Heerdt S, Kunt T, Bockisch A and Beyer J. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. *J Clin Endocrinol Metab* 2000;85:1890-4.
356. Milhaud G, Tubiana M, Parmentier C and Coutris G. Epithelioma de la thyroïde secretant de la thyrocalcitonine. *C.R. Acad. Sci (serie D), Paris* 1968;266:608-10.
357. Guilloteau D, Perdrisot D, Calmettes C and et. al. Diagnosis of medullary carcinoma of the thyroid by calcitonin assay using monoclonal antibodies. *J Clin Endocrinol Metab* 1990;71:1064-7.
358. Niccoli P, Wion-Barbot N, Caron P and et.al. Interest of routine measurement of serum calcitonin (CT): study in a large series of thyroidectomized patients. *J Clin Endocrinol Metab* 1997;82:338-41.
359. Wells SA, Baylin SB, Linehan W, Farrell RE, Cox EB, Cooper CW. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. *Ann Surg* 1978;188:139-41.
360. Gagel RF. The abnormal pentagastrin test. *Clin Endocrinol* 1996;44:221-2.

361. Wion-Barbot N, Schuffenecker I, Niccoli P et al. Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families. *Ann Endocrinol* 1997;58:302-8.
362. Barbot N, Calmettes C, Schuffenecker I et al. Pentagastrin stimulation test and early diagnosis of medullary carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1994;78:114-20.
363. Erdogan MF, Gullu S, Baskal N, Uysal AR, Kamel N, Erdogan G. Omeprazole: calcitonin stimulation test for the diagnosis follow-up and family screening in medullary carcinoma of the thyroid gland. *Ann Surg* 1997;188:139-41.
364. Vieira AEF, Mello MP, Elias LLK et al. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia Type 2A. *Horm Metab Res* 2002;34:202-6.
365. Wells SA, Chi DD, toshima K, Dehner LP, Coffin cm, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG and Moley JF. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. *Ann Surg* 1994;220:237-50.
366. Telander RL and Moir CR. Medullary thyroid carcinoma in children. *Semin Pediatr Surg* 1994;3:188-93.
367. Niccoli-Sire P, Murat A, Baudin E, Henry JF, Proye C, Bigorgne JC et al. Early or prophylactic thyroidectomy in MEN2/FMTC gene carriers: results in 71 thyroidectomized patients. *Eur J Endocrinol* 1999;141:468-74.
368. Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler ML, Morange S and Conte-Devolx B. Familial medullary thyroid carcinoma (FMTC) with non-cysteine RET mutations: phenotype-genotype relationship in large series of patients. *J Clin Endocrinol Metab* 2001;86:3756-53.
369. Body JJ, Chanoine JP, Dumon JC and Delange F. Circulating calcitonin levels in healthy children and subjects with congenital hypothyroidism from birth to adolescence. *J Clin Endocrinol Metab* 1993;77:565-7.
370. Gharib H, Kao PC and Heath H. Determination of silica-purified plasma calcitonin for the detection and management of medullary thyroid carcinoma: comparison of two provocative tests. *Mayo Clin Proc* 1987;62:373-8.
371. Telander R, Zimmerman D, Sizemore GW, van Heerden JA and Grant CS. Medullary carcinoma in children. Results of early detection and surgery. *Arch Surg* 1989;124:841-3.
372. Calmettes C, Ponder BA, Fisher JA and Raue F. Early diagnosis of multiple endocrine neoplasia type 2 syndrome: consensus statement. European community concerted action: medullary thyroid carcinoma. *Eur J Clin Invest* 1992;22:755-60.
373. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A et al. Prognostic factors for survival and biochemical cure in medullary thyroid carcinoma: results in 899 patients. *Clin Endocrinol* 1998;48:265-73.
374. Machens A, Gimm O, Ukkat J et al. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. *Cancer* 2000;88:1909-15.
375. Fugazzola L, Pinchera A, Lucchetti F et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. *Internat J Biolog Markers* 1994;9:21-4.
376. Vierhapper H, Raber W, Bieglmayer C and et.al. Routine measurement of plasma calcitonin in nodular thyroid diseases. *J Clin Endocrinol Metab* 1997;82:1589-93.
377. Ferreira-Valbuena H, Fernandez de Arguello E, Campos G, Ryder E and Avellaneda A. Serum concentration of calcium and calcitonin in hyperthyroidism caused by Graves' disease. *Invest Clin* 1991;32:109-14.
378. Lips CJM, Hoppener JWM and Thijssen JHH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. *Ann Clin Biochem* 2001;38:168-79.
379. Niccoli P, Brunet Ph, Roubicek C, Roux F, Baudin E, Lejeune PJ et al. Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. *Eur J Endocrinol* 1995;132:75-81.
380. Snider RH, Nysten ES and Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. *J Invest Med* 1997;47:552-60.

381. Russwurm S, Wiederhold M, Oberhoffer M et al. Molecular aspects and natural source of Procalcitonin. *Clin Chem Lab Med* 1999;37:789-97.
382. Niccoli P, Conte-Devolx B, Lejeune PJ, Carayon P, Henry JF, Roux F et al. Hypercalcitoninemia in conditions other than medullary cancers of the thyroid. *Ann Endocrinol* 1996;57:15-21.
383. Baudin E, Bidart JM, Rougier P et al. Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. *J Clin Endocrinol Metab* 1999;84:114-20.
384. DeLellis RA. C-Cell hyperplasia. In: Rosai J., Carangiu M.L., DeLellis R.A. eds: *Atlas of Tumor Pathology*, 3rd. series, Fasc 5: tumors of the thyroid gland. Washington DC, Armed Forces Institute of Pathology. 1992;:247-58.
385. Guyetant S, Wion-Barbot N and Rousselet MC. C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective study of 112 cases. *Hum Pathol* 1994;25:514-21.
386. Albores-Saavedra J, Monforte H, Nadji M and Morales AR. C-Cell hyperplasia in thyroid tissue adjacent to follicular cell tumor. *Hum Pathol* 1988;19:795-9.
387. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the international RET mutation consortium. *J Intern Med* 1995;238:243-6.
388. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. *JAMA* 1996;276:1575-9.
389. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G et al. Biological properties of RET with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma and Hirschsprung's disease phenotype. *Cancer Res* 1997;57:2870-2.
390. Heshmati HM, Gharib H, Khosla S et al. Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. *Mayo Clin Proc* 1997;72:430-6.
391. Berndt I, Reuter M, Saller B et al. A new hot spot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. *J Clin Endocrinol Metab* 1998;83:770-4.
392. Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WKF and Heitz PU. RET proto-oncogene point mutations in sporadic neuroendocrine tumors. *J Clin Endocrinol Metab* 1996;81:2041-6.
393. Conte-Devolx B, Schuffenecker I, Niccoli P, Maes B, Boneu A, Barbot N et al. Multiple Endocrine Neoplasia Type 2: Management of patients and subjects at risk. *Horm Res* 1997;47:221-6.
394. Smith DP, Houghton C and Ponder BA. Germline mutation of RET codon 883 in two cases of de novo MEN2B. *Oncogene* 1997;15:1213-7.
395. Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix A, Wells SA Jr et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. *J Hum Genet* 1994;55:1076-82.
396. Moers AMJ, Landsvater RM, Schaap C, van Veen JM, de Valk IAJ, Blijham GH et al. Familial medullary thyroid carcinoma: not a distinct entity/ Genotype-phenotype correlation in a large family: familial medullary thyroid carcinoma revisited. *Am J Med* 1996;101:634-41.
397. Dunn JT. Iodine deficiency - the next target for elimination. *N Engl J Med* 1992;326:267-8.
398. Delange F. Correction of iodine deficiency: benefits and possible side effects. *Eur J Endocrinol* 1995;132:542-3.
399. Dunn JT. Whats happening to our iodine. *J Clin Endocrinol Metab* 1998;83:3398-3400.
400. Knudsen N, Christiansen E, Brandt-Christensen M, Nygaard B and Perrild H. Age- and sex-adjusted iodine/creatinine ratio. A new standard in epidemiological surveys? Evaluation of three different estimates of iodine excretion based on casual urine samples and comparison to 24 h values. *Eur J Clin Nutr* 2000;54:361-3.
401. Aumont G and Tressol JC. Improved routine method for the determination of total iodine in urine and milk. *Analyst* 1986;111:841-3.
402. Unak P, Darcan S, Yurt F, Biber Z and Coker M. Determination of iodine amounts in urine and water by isotope dilution analysis. *Biol Trace Elem Res* Winter 1999;71-2:463-70.
403. Kilbane MT, Ajja RA, Weetman AP, Dwyer R, McDermott EWM, O'Higfins NJ and Smyth PPA. Tissue Iodine content and serum mediated 125I uptake blocking activity in breast cancer. *J Clin Endocrinol Metab* 2000;85:1245-50.

404. Liberman CS, Pino SC, Fang SL, Braverman LE and Emerson CH. Circulating iodine concentrations during and after pregnancy. *J Clin Endocrinol Metab* 1998;83:3545-9.
405. Vought RL, London WT, Lutwak L and Dublin TD. Reliability of estimates of serum inorganic iodine and daily faecal and urinary iodine excretion from single casual specimens. *J Clin Endocrinol Metab* 1963;23:1218-28.
406. Smyth PPA, Darke C, Parkes AB, Smith DF, Hetherington AM and Lazarus JH. Assessment of goitre in an area of endemic iodine deficiency. *Thyroid* 1999;9:895-901.
407. Thomson CD, Smith TE, Butler KA and Packer MA. An evaluation of urinary measures of iodine and selenium status. *J Trace Elem Med and Biol* 1996;10:214-22.
408. Als C, Helbling A, Peter K, Haldimann M, Zimmerli B and Gerber H. Urinary iodine concentration follows a circadian rhythm: A study with 3023 spot urine samples in adults and children. *J Clin Endocrinol Metab* 2000;85:1367-9.
409. Lightowler H and Davis JG. Iodine intake and iodine deficiency in vegans as assessed by the duplicate-portion technique and urinary iodine excretion. *Br. J Nutr* 1999;80:529-35.
410. Utiger RD. Maternal hypothyroidism and fetal development. *N Engl J Med* 1999;341:601-2.
411. Aboul-Khair S, Crooks J, Turnbull AC and Hytten FE. The physiological changes in thyroid function during pregnancy. *Clin Sci* 1964;27:195-207.
412. Smyth PPA, Smith DF, Radcliff M and O'Herlihy C. Maternal iodine status and thyroid volume during pregnancy: correlation with neonatal intake. *J Clin Endocrinol Metab* 1997;82:2840-3.
413. Gunton JE, Hams GH, Fiegert M and McElduff A. Iodine deficiency in ambulatory participants at a Sydney teaching hospital: Is Australia truly iodine replete? *Med J Aust* 1999;171:467-70.
414. Smyth PPA. Variation in iodine handling during normal pregnancy. *Thyroid* 1999;9:637-42.
415. Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc. National Academic Press 2001
416. Koutras DA, Papadopoulos SN, Sfontouris JG and Rigopoulos GA. Comparison of methods for measuring the plasma inorganic iodine and the absolute iodine uptake by the thyroid gland. *J Clin Endocrinol Metab* 1968;28:757-60.
417. Mizukami Y, Michigishi T, Nonomura A, Hashimoto T, Tonami N, Matsubara F et al. Iodine-induced hypothyroidism: a clinical and histological study of 28 patients. *J Clin Endocrinol Metab* 1993;76:466-71.
418. Heymann WR. Potassium iodide and the Wolff-Chaikhoff effect: relevance for the dermatologist. *J Am Acad Dermatol* 2000;42:490-2.
419. Stanbury JB, Ermans AE, Bourdoux P, Todd C, Oken E, Tonglet R, Bidor G, Braverman LE and Medeiros-Neto G. Iodine-induced hyperthyroidism: occurrence and epidemiology. *Thyroid* 1998;8:83-100.
420. Roti E and Uberti ED. Iodine excess and hyperthyroidism. *Thyroid* 2001;5:493-500.
421. Baltisberger BL, Minder CE and Burgi H. Decrease of incidence of toxic nodular goitre in a region of Switzerland after full correction of mild iodine deficiency. *Eur J Endocrinol* 1995;132:546-9.
422. Bacher-Stier RG, Totsch M, Kemmler G, Oberaigner W and Moncayo R. Incidence and clinical characteristics of thyroid carcinoma after iodine prophylaxis in an endemic goiter country. *Thyroid* 1997;7:733-41.
423. Barakat MCD, Hetherington AM, Smyth PPA and Leslie H. Hypothyroidism secondary to topical iodine treatment in infants with spina bifida. *Acta Paediat* 1994;83:741-3.
424. Martino E, Safran M, Aghino-Lombardi F, Rajatanavin R, Lenziardi M, Fay M et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. *Ann Intern Med* 1984;101:28-34.
425. Rose NR, Rasooly L, Saboori AM and Burek CL. Linking iodine with autoimmune thyroiditis. *Environmental Health Perspectives* 1999;107:749-52.
426. Premawardhana LDKEPA, Smyth PPA, Wijeyaratne C, Jayasinghe A, De Silva H and Lazarus JH. Increased prevalence of thyroglobulin antibodies in Sri Lankan schoolgirls - is iodine the cause? *Eur J Endocrinol* 2000;143:185-8.
427. Costa A, Testori OB, Cenderelli C, Giribone G and Migliardi M. Iodine content of human tissues after administration of iodine containing drugs or contrast media. *J Endocrinol Invest* 1978;1:221-5.

428. May W, Wu D, Eastman C, Bourdoux P and Maberly G. Evaluation of automated urinary iodine methods: problems of interfering substances identified. *Clin Chem* 1990;35:865-9.
429. Lauber K. Iodine determination in biological material. Kinetic measurement of the catalytic activity of iodine. *Analyt Chem* 1975;47:769-71.
430. Mantel M. Improved method for the determination of iodine in urine. *Clin Chim Acta* 1971;33:39-44.
431. Dunn JT, Crutchfield HE, Gutenkunst R and Dunn AD. Two simple methods for measuring iodine in urine. *Thyroid* 1993;3:119-23.
432. May SL, May WA, Bourdoux PP, Pino S, Sullivan KM and Maberly GF. Validation of a simple, manual urinary iodine method for estimating the prevalence of iodine-deficiency disorders and interlaboratory comparison with other methods. *J Clin Nutr* 1997;65:1441-5.
433. Ohashi T, Yamaki M, Pandav SC, Karmarkar GM and Irie M. Simple microplate method for determination of urinary iodine. *Clin Chem* 2000;46:529-36.
434. Rendell J, Seybold S and Borner W. Urinary iodine determined by paired-ion reverse-phase HPLC with electrochemical detection. *Clin Chem* 1994;40:908-13.
435. Tsuda K, Namba H, Nomura T, Yokoyama N, Yamashita S, Izumi M and Nagataki S. Automated Measurement of urinary iodine with use of ultraviolet radiation. *Clin Chem* 1995;41:581-5.
436. Haldimann M, Zimmerli B, Als C and Gerber H. Direct determination of urinary iodine by inductively coupled plasma mass spectrometry using isotope dilution with iodine-129. *Clin Chem* 1998;44:817-24.
437. Mura P, Piriou A, Guillard O, Sudre Y and Reiss D. Dosage des iodures urinaires par electrode specifique: son interet au cours des dysthyroides. *Ann Biol Clin* 1985;44:123-6.
438. Allain P, Berre S, Krari N, Laine-Cessac P, Le Bouil A, Barbot N, Rohmer V and Bigorgne JC. Use of plasma iodine assays for diagnosing thyroid disorders. *J Clin Pathol* 1993;46:453-5.
439. Vander JB, Gaston EA and Dawber TR. The significance of nontoxic thyroid nodules: Final report of a 15-year study of the incidence of thyroid malignancy. *Ann Intern Med* 1968;69:537-40.
440. Rojeski MT and Gharib H. Nodular thyroid disease: Evaluation and management. *N Engl J Med* 1985;313:428-36.
441. Mazzaferri EL. Management of a solitary thyroid nodule. *N Engl J Med* 1993;328:553-9.
442. Kirkland RT and Kirkland JL. Solitary thyroid nodules in 30 children and report of a child with thyroid abscess. *Pediatrics* 1973;51:85-90.
443. Rallison ML, Dobyns EM, Keating FR, Rall J and Tyler E. Thyroid nodularity in children. *JAMA* 1975;233:1069-72.
444. Khurana KK, Labrador E, Izquierdo R, Mesonero CE and Pisharodi LR. The role of fine-needle aspiration biopsy in the management of thyroid nodules in children, adolescents and young adults: A multi-institutional study. *Thyroid* 1999;4:383-6.
445. Aghini-Lombardi F, Antonangeli L, Martino E, Vitti P, Maccherini D, Leoli F, Rago T, Grasso L, Valeriano R, Balestrieri A and Pinchera A. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopanano Survey. *J Clin Endocrinol Metab* 1999;84:561-6.
446. Hamburger JI, Husain M, Nishiyama R, Nunez C and Solomon D. Increasing the accuracy of fine-needle biopsy for thyroid nodules. *Arch Pathol Lab Med* 1989;113:1035-41.
447. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK and Holzer S. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. *Cancer (Cytopathol)* 2000;89:202-17.
448. Leenhardt L, Hejblum G, Franc B, Du Pasqueir Fediaevsky L, Delbot T, De Guillouzic D, Menegaux F, Guillausseau C, Hoang C, Turpin G and Aurengo A. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. *J Clin Endocrinol Metab* 1999;84:24-8.
449. Braga M, Cavalcanti TC, Collaco LM and Graf H. Efficacy of ultrasound-guided fine-needle aspiration biopsy in the diagnosis of complex thyroid nodules. *J Clin Endocrinol Metab* 2001;86:4089-91.
450. Cochand-Priollet B, Guillausseau P, Chagnon S, Hoang C, Guillausseau-Scholer C, Chanson P, Dahan H, Warnet A, Tran Ba Huy PT and Valleur P. The diagnostic value of fine-needle aspiration biopsy under ultrasonography in nonfunctional thyroid nodules: a prospective study comparing cytologic and histologic findings. *Am J Med* 1994;97:152-7.
451. Takashima S, Fukuda H and Kobayashi T. Thyroid nodules: Clinical effect of ultrasound-guided fine needle aspiration biopsy. *J Clin Ultrasound* 1994;22:535-42.
452. Gharib H. Fine-needle aspiration biopsy of thyroid nodules: Advantages, limitations and effect. *Mayo Clin Proc* 1994;69:44-9.

453. Hamberger B, Gharib H, Melton LF III, Goellner JR and zinsmeister AR. Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. *Am J Med* 1982;73:381-4.
454. Grant CS, Hay ID, Gough IR, McCarthy PM and Goellner JR. Long-term follow-up of patients with benign thyroid fine-needle aspiration cytologic diagnoses. *Surgery* 1989;106:980-6.
455. Liel Y and Barchana M. Long-term follow-up of patients with initially benign fine-needle aspirations. *Thyroid* 2001;11:775-8.
456. Belfiore A, La Rosa G, La Porta GA, Giuffrida D, Milazzo G, Lupo L, Regalbutto C and V. R. Cancer Risk in patients with cold thyroid nodules: Relevance of iodine intake, sex, age and multinodularity. *J Amer Med* 1992;93:363-9.
457. Tuttle RM, Lemar H and Burch HB. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. *Thyroid* 1998;8:377-83.
458. Kumar H, Daykin J, Holder R, Watkinson JC, Sheppard M and Franklyn JA. Gender, clinical findings and serum thyrotropin measurements in the prediction of thyroid neoplasia in 1005 patients presenting with thyroid enlargement and investigated by fine-needle aspiration cytology. *Thyroid* 1999;11:1105-9.
459. Moosa M and Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. *J Clin Endocrinol Metab* 1997;82:2862-6.
460. Oertel YC. A pathologist trying to help endocrinologists to interpret cytology reports from thyroid aspirates. *J Clin Endocrinol Metab* 2002;87:1459-61.
461. De Micco, Zoro P, Garcia S, Skoog L, Tani EM, C. PK and Henry JF. Thyroid peroxidase immunodetection as a tool to assist diagnosis of thyroid nodules on fine-needle aspiration biopsy. *Eur J Endocrinol* 1994;131:474-9.
462. Faroux MJ, Theobald S, Pluot M, Patey M and Menzies D. Evaluation of the monoclonal antithyropoxidase MoAb47 in the diagnostic decision of cold thyroid nodules by fine-needle aspiration. *Pathol Res Pract* 1997;193:705-12.
463. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A and Kubo T. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. *Cancer* 1999;85:2475-84.
464. Medeiros-Neto G, Nascimento MC, Bisi H, Alves VA, Longatto-Filho A and Kanamura CT. Differential reactivity for Galectin-3 in Hurthle Cell Adenomas and Carcinomas. *Endocr Pathol* 2001;12:275-9.
465. Saggiorato E, Cappia S, De Guili P, Mussa A, Pancani G, Caraci P, Angeli A and Orlandi F. Galectin - 3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular carcinoma. *J Clin Endocrinol Metab* 2001;86:5152-8.
466. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orkandi F, Nardi F, Vacchione A, Tecce R and Larsson O. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. *Lancet* 2001;357:1644-50.
467. Goellner JR. Problems and pitfalls in thyroid cytology. *Monogr Pathol* 1997;39:75-93.
468. Oertel YC, O. J. Diagnosis of benign thyroid lesions: fine-needle aspiration and histopathologic correlation. *Ann Diagn Pathol* 1998;2:250-63.
469. Baldet L, Manderscheid JC, Glinoeer D, Jaffiol C, Coste-Seignovert B and Percheron C. The management of differentiated thyroid cancer in Europe in 1988. Results of an international survey. *Acta Endocrinol (Copenh)* 1989;120:547-58.
470. Baloch ZW, Fleisher S, LiVolsi VA and Gupta PK. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. *Diagn Cytopathol* 2002;26:41-4.
471. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM and Baloch ZW. Immunohistochemical expression of Galectin-3 in benign and malignant thyroid lesions. *Arch Pathol Lab Med* 2002;126:710-13.
472. Leteurtre E, Leroy Z, Pattou F, Wacrenier A, Carnaille B, Proye C and Lecomte-Houcke M. Why do frozen sections have limited value in encapsulated or minimally invasive follicular carcinoma of the thyroid? *Amer J Clin Path* 2001;115:370-4.
473. Stojadinovic A, Ghossein RA, Hoos A, Urist MJ, Spiro RH, Shah JP, Brennan MF, Shaha AR and Singh B. Hurthle cell carcinoma: a critical histopathologic appraisal. *J Clin Oncol* 2001;19:2616-25.
474. Carmeci C, Jeffrey RB, McDougall IR, Nowels KW and Weigel RJ. Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. *Thyroid* 1998;8:283-9.

475. Yang GCH, Liebeskind D and Messina AV. Ultrasound-guided fine-needle aspiration of the thyroid assessed by ultrafast papanicolaou stain: Data from 1135 biopsies with a two- six-year follow-up. *Thyroid* 2001;6:581-9.
476. Fisher DA, Dussault JH, Foley TP, Klein AH, LaFranchi S, Larsen PR, Mitchell NL, Murphey WH and Walfish PG. Screening for congenital hypothyroidism: results of screening one million North American infants. *J Pediatr* 1979;94:700.
477. Brown AL, Fernhoff PM, Milner J, McEwen C and Elsas LS. Racial differences in the incidence of congenital hypothyroidism. *J Pediatr* 1981;99:934-.
478. LaFranchi SH, Dussault JH, Fisher DA, Foley TP and Mitchell ML. Newborn screening for congenital hypothyroidism: Recommended guidelines. *Pediatrics* 1993;91:1203-9.
479. Gruters A, Delange F, Giovanelli G, Klett M, Richiccioli P, Torresani T et al. Guidelines for neonatal screening programmes for congenital hypothyroidism. *Pediatr* 1993;152:974-5.
480. Toublanc JE. Guidelines for neonatal screening programs for congenital hypothyroidism. *Acta Paediatr* 1999;88 Suppl 432:13-4.
481. Vulmsa T, Gons MH and de Vijlder JJ. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. *N Engl J Med* 1989;321:13-6.
482. Gruneiro-Papendieck L, Prieto L, Chiesa A, Bengolea S, Bossi G and Bergada C. Usefulness of thyroxine and free thyroxine filter paper measurements in neonatal screening for congenital hypothyroidism of preterm babies. *J Med Screen* 2000;7:78-81.
483. Hanna DE, Krainz PL, Skeels MR, Miyahira RS, Sesser DE and LaFranchi SH. Detection of congenital hypopituitary hypothyroidism: Ten year experience in the Northwest Regional Screening Program. *J Pediatr* 1986;109:959-64.
484. Fisher DA. Hypothyroxinemia in premature infants: is thyroxine treatment necessary? *Thyroid* 1999;9:715-20.
485. Wang ST, Pizzalato S and Demshar HP. Diagnostic effectiveness of TSH screening and of T4 with secondary TSH screening for newborn congenital hypothyroidism. *Clin Chim Acta* 1998;274:151-8.
486. Delange F. Screening for congenital hypothyroidism used as an indicator of the degree of IDD and its control. *Thyroid* 1998;8:1185-92.
487. Law WY, Bradley DM, Lazarus JH, John R and Gregory JW. Congenital hypothyroidism in Wales (1982-93): demographic features, clinical presentation and effects on early neurodevelopment. *Clin Endocrinol* 1998;48:201-7.
488. Mei JV, Alexander JR, Adam BW and Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. *J Nutr* 2001;131:1631S-6S.
489. LaFranchi SH, Hanna CE, Krainz PL, Skeels MR, Miyahira RS and Sesser DE. Screening for congenital hypothyroidism with specimen collection at two time periods: Results of the Northwest Regional Screening Program. *J Pediatr* 1985;76:734-40.
490. Zakarija M, McKenzie JM and Eidson MS. Transient neonatal hypothyroidism: Characterization of maternal antibodies to the Thyrotropin Receptor. *J Clin Endocrinol Metab* 1990;70:1239-46.
491. Matsuura N, Yamada Y, Nohara Y, Konishi J, Kasagi K, Endo K, Kojima H and Wataya K. Familial neonatal transient hypothyroidism due to maternal TSH-binding inhibitor immunoglobulins. *N Engl J Med* 1980;303:738-41.
492. McKenzie JM and Zakaria M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. *Thyroid* 1992;2:155-9.
493. Vogiatzi MG and Kirkland JL. Frequency and necessity of thyroid function tests in neonates and infants with congenital hypothyroidism. *Pediatr* 1997;100.
494. Pohlenz J, Rosenthal IM, Weiss RE, Jhiang SM, Burant C and Refetoff S. Congenital hypothyroidism due to mutations in the sodium/iodide symporter. Identification of a nonsense mutation producing a downstream cryptic 3' splice site. *J Clin Invest* 1998;101:1028-35.
495. Nordyke RA, Reppun TS, Mandanay LD, Wood JC, Goldstein AP and Miyamoto LA. Alternative sequences of thyrotropin and free thyroxine assays for routine thyroid function testing. Quality and cost. *Arch Intern Med* 1998;158:266-72.